Base de dados : MEDLINE
Pesquisa : D12.776.124.790.223.800 [Categoria DeCS]
Referências encontradas : 5242 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 525 ir para página                         

  1 / 5242 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470687
[Au] Autor:Li Y; Zhang M; Liu X; Cui W; Rampersad S; Li F; Lin Z; Yang P; Li H; Sheng C; Cheng X; Qu S
[Ad] Endereço:Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
[Ti] Título:Correlates and prevalence of hypogonadism in patients with early- and late-onset type 2 diabetes.
[So] Source:Andrology;5(4):739-743, 2017 07.
[Is] ISSN:2047-2927
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study aims to compare the prevalence of hypogonadism between male patients with early-onset type 2 diabetes mellitus (T2DM) and late-onset type 2 diabetes. A total of 122 male patients with early-onset T2DM (diagnosis age ≤40 years) and 100 male patients with late-onset T2DM (diagnosis age >40 years) were recruited from our in-patient department between 1 January 2013 and 28 December 2015. Serum FSH, LH, testosterone, lipid profile, uric acid, HbA1c, and beta-cell function were determined in blood samples. The diagnosis of hypogonadism was based on the levels of LH, FSH, and total testosterone. The mean onset age was 29.86 ± 6.31 and 54.47 ± 9.97 years old in the early-onset group and late-onset group, respectively. Compared with late-onset T2DM, those with early-onset T2DM had a higher proportion of new-onset diabetes, were more likely to be obese, and had worse glycemic control, lipid control, and lower sex hormone-binding globulin (SHBG). The prevalence of hypogonadism was much higher in the early-onset group than in the late-onset group (48.0% vs. 26.7%, p < 0.05). The rate of secondary hypogonadism in the early-onset group and late-onset group were 44.3% and 25.0%, respectively (p < 0.05). Obesity, waist circumference, and SHBG were significantly associated with serum total testosterone level in all, early-onset, and late-onset T2DM. Both all and early-onset T2DM groups had positive correlations between total testosterone and fasting C-peptide, total cholesterol, triglycerides, and uric acid. Our results indicate that in a population of admission to a large urban hospital in China, the prevalence of hypogonadism was higher in the patients with early-onset T2DM than that of late-onset T2DM. This prevalence might be attributable to greater obesity, worse lipid control, and lower SHBG levels in those patients.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/epidemiologia
Hipogonadismo/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Idade de Início
Idoso
Biomarcadores/sangue
Glicemia/análise
China/epidemiologia
Estudos Transversais
Diabetes Mellitus Tipo 2/sangue
Diabetes Mellitus Tipo 2/diagnóstico
Hormônio Foliculoestimulante Humano/sangue
Hemoglobina A Glicada/análise
Hospitais Urbanos
Seres Humanos
Hipogonadismo/sangue
Hipogonadismo/diagnóstico
Insulina/sangue
Lipídeos/sangue
Hormônio Luteinizante/sangue
Masculino
Meia-Idade
Admissão do Paciente
Prevalência
Fatores de Risco
Globulina de Ligação a Hormônio Sexual/análise
Testosterona/sangue
Ácido Úrico/sangue
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers); 0 (Blood Glucose); 0 (Follicle Stimulating Hormone, Human); 0 (Glycated Hemoglobin A); 0 (Insulin); 0 (Lipids); 0 (Sex Hormone-Binding Globulin); 0 (hemoglobin A1c protein, human); 268B43MJ25 (Uric Acid); 3XMK78S47O (Testosterone); 9002-67-9 (Luteinizing Hormone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1111/andr.12360


  2 / 5242 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27771738
[Au] Autor:Brahimaj A; Muka T; Kavousi M; Laven JS; Dehghan A; Franco OH
[Ad] Endereço:Department of Epidemiology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, the Netherlands. a.brahimaj@erasmusmc.nl.
[Ti] Título:Serum dehydroepiandrosterone levels are associated with lower risk of type 2 diabetes: the Rotterdam Study.
[So] Source:Diabetologia;60(1):98-106, 2017 01.
[Is] ISSN:1432-0428
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:AIMS/HYPOTHESIS: Previous literature documents controversial results for the impact of dehydroepiandrosterone (DHEA) in glucose metabolism. We aimed to assess the associations between serum levels of DHEA and its main derivatives DHEA sulphate (DHEAS) and androstenedione, as well as the ratio of DHEAS to DHEA, and risk of type 2 diabetes. METHODS: We used data on serum levels of DHEA, DHEAS and androstenedione from 5189 middle-aged and elderly men and women from the prospective population-based Rotterdam Study. Type 2 diabetes was defined as a fasting blood glucose ≥7.0 mmol/l or a non-fasting blood glucose ≥11.1 mmol/l. RESULTS: During a median follow-up of 10.9 years, 643 patients with incident type 2 diabetes were identified. After adjusting for age, sex, cohort, fasting status, fasting glucose and insulin, and BMI, both serum DHEA levels (per 1 unit natural log-transformed, HR 0.76, 95% CI 0.67, 0.87) and serum DHEAS levels (per 1 unit natural log-transformed, HR 0.82, 95% CI 0.73, 0.92) were inversely associated with risk of type 2 diabetes in the total population. Further adjustment for alcohol, smoking, physical activity, prevalent cardiovascular disease, serum total cholesterol, use of lipid-lowering medications, systolic BP, treatment for hypertension, C-reactive protein, oestradiol and testosterone did not substantially affect the association between DHEA and incident type 2 diabetes (per 1 unit natural log-transformed, HR 0.80, 95% CI 0.65, 0.99), but abolished the association between DHEAS and type 2 diabetes. Androstenedione was not associated with risk of type 2 diabetes, nor was DHEAS to DHEA ratio. CONCLUSIONS/INTERPRETATION: DHEA serum levels might be an independent marker of type 2 diabetes.
[Mh] Termos MeSH primário: Desidroepiandrosterona/sangue
Diabetes Mellitus Tipo 2/sangue
Diabetes Mellitus Tipo 2/epidemiologia
[Mh] Termos MeSH secundário: Idoso
Androstenodiona/sangue
Estudos de Coortes
Sulfato de Desidroepiandrosterona/sangue
Diabetes Mellitus Tipo 2/metabolismo
Feminino
Seres Humanos
Masculino
Meia-Idade
Fatores de Risco
Globulina de Ligação a Hormônio Sexual/metabolismo
Testosterona/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Sex Hormone-Binding Globulin); 3XMK78S47O (Testosterone); 409J2J96VR (Androstenedione); 459AG36T1B (Dehydroepiandrosterone); 57B09Q7FJR (Dehydroepiandrosterone Sulfate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  3 / 5242 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28796064
[Au] Autor:Cui YR; Guo YH; Qiao SD; Leng LF; Xie ZH; Chen H; Wang XL
[Ad] Endereço:aReproductive Medical Center, the Third Affiliated Hospital of Zhengzhou University bDepartment of Medical Genetics and Cell Biology, School of Basic Medical Sciences, Zhengzhou University cReproductive Medical Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
[Ti] Título:Correlation between SHBG gene polymorphism and male infertility in Han population of Henan province of China: A STROBE-compliant article.
[So] Source:Medicine (Baltimore);96(32):e7753, 2017 Aug.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Human sex hormone binding globulin (SHBG) level alteration and SHBG gene mutations, especially in rs6259 and rs727428 loci, are associated with male infertility. In this study, the rs6259 and rs727428 loci in SHBG gene were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to explore the direct relation between these 2 loci and male infertility in Han population of Henan province and to provide information for the pathogenesis, diagnosis, and treatment of male infertility.A total of 366 male Han individuals in Henan province were enrolled in this study. Of the 366 male individuals, 183 infertility patients were served as infertility group and other 183 normal individuals as a control group. SHBG gene rs6259 and rs727428 locus polymorphisms were detected by PCR-RFLP in all patients. Also, genotype frequencies, allele frequency, and haplotype were all analyzed in both groups.There were statistical differences in A allele frequency (P = .017) and GA genotype frequency (P = .016) of SHBG gene rs6259 locus and in CC genotype frequency of SHBG gene rs727428 locus (P = .034) between the 2 groups.Male infertility is associated with GA genotype and A allele of rs6259 locus, as well as CC genotype of rs727428 locus in SHBG gene.
[Mh] Termos MeSH primário: Infertilidade Masculina/etnologia
Infertilidade Masculina/genética
Globulina de Ligação a Hormônio Sexual/genética
[Mh] Termos MeSH secundário: Adulto
China/epidemiologia
Grupos Étnicos
Frequência do Gene
Estudo de Associação Genômica Ampla
Genótipo
Haplótipos
Seres Humanos
Masculino
Meia-Idade
Reação em Cadeia da Polimerase
Polimorfismo de Nucleotídeo Único
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Sex Hormone-Binding Globulin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170827
[Lr] Data última revisão:
170827
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007753


  4 / 5242 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28723965
[Au] Autor:Dargham SR; Ahmed L; Kilpatrick ES; Atkin SL
[Ad] Endereço:Infectious Disease Epidemiology Group, Weill Cornell Medicine, Doha, Qatar.
[Ti] Título:The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population.
[So] Source:PLoS One;12(7):e0181467, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The prevalence of polycystic ovary syndrome (PCOS) in the Qatari population is unknown and hence the estimated impact on the local population cannot be determined. The purpose of this study was to estimate the prevalence and metabolic features of PCOS among Qatari women. DESIGN: Cross sectional analysis. PATIENTS: 3,017 Qatari subjects volunteered to be phenotyped and genotyped for the Qatar Biobank from which all women between the ages of 18-40 years were identified (750). MEASUREMENTS: 720 women had testosterone and sex hormone binding globulin (SHBG) measurements. PCOS was diagnosed according the National Institute of Health (NIH) Guidelines of a raised androgen level (free androgen index >4.5 or a raised total testosterone) and menstrual irregularity after the exclusion of other conditions. RESULTS: All results are reported as mean value of PCOS versus control. 87 of 720 women fulfilled the NIH guidelines (12.1%) for PCOS specifically using a free androgen index greater than 4.5 or a total testosterone greater than 2.7nmol/l and menstrual irregularity. Subjects were heavier with a more metabolic profile of a greater systolic and diastolic blood pressure, higher levels of C reactive protein, insulin (p<0.01) and HbA1c (P<0.02), and decreased HDL levels (p<0.01). Pulse wave velocity as a marker of arterial stiffness was also increased (p<0.05). CONCLUSIONS: By NIH guidelines the prevalence of PCOS in this Qatari cohort was 12.1% that would likely reflect 20% by Rotterdam criteria, with a markedly more metabolic phenotype than Qatari controls.
[Mh] Termos MeSH primário: Síndrome do Ovário Policístico/diagnóstico
Síndrome do Ovário Policístico/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Pressão Sanguínea/fisiologia
Índice de Massa Corporal
Estudos Transversais
Feminino
Seres Humanos
Síndrome do Ovário Policístico/metabolismo
Prevalência
Catar
Globulina de Ligação a Hormônio Sexual/metabolismo
Avaliação de Sintomas
Testosterona/sangue
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sex Hormone-Binding Globulin); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181467


  5 / 5242 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28673896
[Au] Autor:Bermon S; Garnier PY
[Ad] Endereço:Université Côte d'Azur, LAMHESS Nice, France and Monaco Institute of Sports Medicine and Surgery, Monaco.
[Ti] Título:Serum androgen levels and their relation to performance in track and field: mass spectrometry results from 2127 observations in male and female elite athletes.
[So] Source:Br J Sports Med;51(17):1309-1314, 2017 Sep.
[Is] ISSN:1473-0480
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To describe and characterise serum androgen levels and to study their possible influence on athletic performance in male and female elite athletes. METHODS: 2127 observations of competition best performances and mass spectrometry-measured serum androgen concentrations, obtained during the 2011 and 2013 International Association of Athletics Federations World Championships, were analysed in male and female elite track and field athletes. To test the influence of serum androgen levels on performance, male and female athletes were classified in tertiles according to their free testosterone (fT) concentration and the best competition results achieved in the highest and lowest fT tertiles were then compared. RESULTS: The type of athletic event did not influence fT concentration among elite women, whereas male sprinters showed higher values for fT than male athletes in other events. Men involved in all throwing events showed significantly (p<0.05) lower testosterone and sex hormone binding globulin than men in other events. When compared with the lowest female fT tertile, women with the highest fT tertile performed significantly (p<0.05) better in 400 m, 400 m hurdles, 800 m, hammer throw, and pole vault with margins of 2.73%, 2.78%, 1.78%, 4.53%, and 2.94%, respectively. Such a pattern was not found in any of the male athletic events. CONCLUSION: Female athletes with high fT levels have a significant competitive advantage over those with low fT in 400 m, 400 m hurdles, 800 m, hammer throw, and pole vault.
[Mh] Termos MeSH primário: Androgênios/sangue
Atletas
Desempenho Atlético
Atletismo
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Masculino
Espectrometria de Massas
Globulina de Ligação a Hormônio Sexual/análise
Testosterona/sangue
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgens); 0 (Sex Hormone-Binding Globulin); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1136/bjsports-2017-097792


  6 / 5242 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28664912
[Au] Autor:Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ
[Ad] Endereço:Stoller Biomarker Discovery Centre and Pathology Node, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road Manchester, Manchester, UK.
[Ti] Título:A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
[So] Source:Br J Cancer;117(5):666-674, 2017 Aug 22.
[Is] ISSN:1532-1827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: There is an urgent need for biomarkers for the early detection of ovarian cancer (OC). The purpose of this study was to assess whether changes in serum levels of lecithin-cholesterol acyltransferase (LCAT), sex hormone-binding globulin (SHBG), glucose-regulated protein, 78 kDa (GRP78), calprotectin and insulin-like growth factor-binding protein 2 (IGFBP2) are observed before clinical presentation and to assess the performance of these markers alone and in combination with CA125 for early detection. METHODS: This nested case-control study used samples from the United Kingdom Collaborative Trial of Ovarian Cancer Screening trial. The sample set consisted of 482 serum samples from 49 OC subjects and 31 controls, with serial samples spanning up to 7 years pre-diagnosis. The set was divided into the following: (I) a discovery set, which included all women with only two samples from each woman, the first at<14 months and the second at >32 months to diagnosis; and (ii) a corroboration set, which included all the serial samples from the same women spanning the 7-year period. Lecithin-cholesterol acyltransferase, SHBG, GRP78, calprotectin and IGFBP2 were measured using ELISA. The performance of the markers to detect cancers pre-diagnosis was assessed. RESULTS: A combined threshold model IGFBP2 >78.5 ng ml : LCAT <8.831 µg ml : CA125 >35 U ml outperformed CA125 alone for the earlier detection of OC. The threshold model was able to identify the most aggressive Type II cancers. In addition, it increased the lead time by 5-6 months and identified 26% of Type I subjects and 13% of Type II subjects that were not identified by CA125 alone. CONCLUSIONS: Combined biomarker panels (IGFBP2, LCAT and CA125) outperformed CA125 up to 3 years pre-diagnosis, identifying cancers missed by CA125, providing increased diagnostic lead times for Type I and Type II OC. The model identified more aggressive Type II cancers, with women crossing the threshold dying earlier, indicating that these markers can improve on the sensitivity of CA125 alone for the early detection of OC.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Antígeno Ca-125/sangue
Detecção Precoce de Câncer/métodos
Proteína 2 de Ligação a Fator de Crescimento Semelhante à Insulina/sangue
Neoplasias Ovarianas/sangue
Neoplasias Ovarianas/diagnóstico
Fosfatidilcolina-Esterol O-Aciltransferase/sangue
[Mh] Termos MeSH secundário: Estudos de Casos e Controles
Feminino
Proteínas de Choque Térmico/sangue
Seres Humanos
Complexo Antígeno L1 Leucocitário/sangue
Neoplasias Ovarianas/patologia
Globulina de Ligação a Hormônio Sexual/metabolismo
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CA-125 Antigen); 0 (Heat-Shock Proteins); 0 (Insulin-Like Growth Factor Binding Protein 2); 0 (Leukocyte L1 Antigen Complex); 0 (Sex Hormone-Binding Globulin); 0 (molecular chaperone GRP78); EC 2.3.1.43 (Phosphatidylcholine-Sterol O-Acyltransferase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170701
[St] Status:MEDLINE
[do] DOI:10.1038/bjc.2017.199


  7 / 5242 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28619249
[Au] Autor:Vihma V; Naukkarinen J; Turpeinen U; Hämäläinen E; Kaprio J; Rissanen A; Heinonen S; Hakkarainen A; Lundbom J; Lundbom N; Mikkola TS; Tikkanen MJ; Pietiläinen KH
[Ad] Endereço:University of Helsinki and Helsinki University Hospital, Heart and Lung Center, Biomedicum C415, Haartmaninkatu 8, 00290 Helsinki, Finland; Folkhälsan Research Center, P.O. Box 63, 00014, University of Helsinki, Finland. Electronic address: veera.vihma@helsinki.fi.
[Ti] Título:Metabolism of sex steroids is influenced by acquired adiposity-A study of young adult male monozygotic twin pairs.
[So] Source:J Steroid Biochem Mol Biol;172:98-105, 2017 Sep.
[Is] ISSN:1879-1220
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Obesity and ageing are associated with lower serum testosterone levels in men. How fat distribution or adipose tissue metabolism, independent of genetic factors and age, are related to sex steroid metabolism is less clear. We studied the associations between adiposity and serum sex hormone concentrations, and mRNA expression of genes regulating sex hormone metabolism in adipose tissue in young adult male monozygotic (MZ) twin pairs. The subjects [n=18 pairs; mean age, 32 years; individual body mass indexes (BMIs) 22-36kg/m ] included 9 male MZ twin pairs discordant for BMI [intra-pair difference (Δ) in BMI ≥3kg/m ]. Sex steroid concentrations were determined by liquid chromatography-tandem mass spectrometry, body composition by dual-energy X-ray absorptiometry and magnetic resonance imaging, and mRNA expressions from subcutaneous adipose tissue by Affymetrix. In BMI-discordant pairs (mean ΔBMI=5.9kg/m ), serum dihydrotestosterone (DHT) was lower [mean 1.9 (SD 0.7) vs. 2.4 (1.0) nmol/l, P=0.040] and mRNA expressions of DHT-inactivating AKR1C2 (P=0.021) and cortisol-producing HSD11B1 (P=0.008) higher in the heavier compared to the leaner co-twins. Serum free 17ß-estradiol (E2) was higher [2.3 (0.5) vs. 1.9 (0.5) pmol/l, P=0.028], and in all twin pairs, serum E2 and estrone concentrations were higher in the heavier than in the leaner co-twins [107 (28) vs. 90 (22) pmol/l, P=0.006; and 123 (43) vs. 105 (27) pmol/l, P=0.025]. Within all twin pairs, i.e. independent of genetic effects and age, 1) the amount of subcutaneous fat inversely correlated with serum total and free testosterone, DHT, and sex hormone-binding globulin (SHBG) concentrations (P<0.01 for all), 2) intra-abdominal fat with total testosterone and SHBG (P<0.05), and 3) liver fat with SHBG (P=0.006). Also, 4) general and intra-abdominal adiposity correlated positively with mRNA expressions of AKR1C2, HSD11B1, and aromatase in adipose tissue (P<0.05). In conclusion, acquired adiposity was associated with decreased serum DHT and increased estrogen concentrations, independent of genetic factors and age. The reduction of DHT could be linked to its increased degradation (by AKR1C2 and HSD11B1) and increased estrogen levels to increased adiposity-related expression of aromatase in adipose tissue.
[Mh] Termos MeSH primário: 11-beta-Hidroxiesteroide Desidrogenase Tipo 1/genética
Aromatase/genética
Hidroxiesteroide Desidrogenases/genética
Obesidade/metabolismo
Globulina de Ligação a Hormônio Sexual/genética
Gordura Subcutânea/metabolismo
[Mh] Termos MeSH secundário: 11-beta-Hidroxiesteroide Desidrogenase Tipo 1/metabolismo
Absorciometria de Fóton
Adulto
Aromatase/metabolismo
Composição Corporal/genética
Cromatografia Líquida
Estudos Transversais
Di-Hidrotestosterona/sangue
Estradiol/sangue
Estrona/sangue
Regulação da Expressão Gênica
Seres Humanos
Hidroxiesteroide Desidrogenases/metabolismo
Masculino
Meia-Idade
Obesidade/genética
Obesidade/patologia
Globulina de Ligação a Hormônio Sexual/metabolismo
Gordura Subcutânea/patologia
Espectrometria de Massas em Tandem
Testosterona/sangue
Gêmeos Monozigóticos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sex Hormone-Binding Globulin); 08J2K08A3Y (Dihydrotestosterone); 2DI9HA706A (Estrone); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); EC 1.1.- (Hydroxysteroid Dehydrogenases); EC 1.1.1.146 (11-beta-Hydroxysteroid Dehydrogenase Type 1); EC 1.1.1.146 (HSD11B1 protein, human); EC 1.1.1.357 (AKR1C2 protein, human); EC 1.14.14.1 (Aromatase); EC 1.14.14.1 (CYP19A1 protein, human)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170617
[St] Status:MEDLINE


  8 / 5242 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28606553
[Au] Autor:Burris J; Rietkerk W; Shikany JM; Woolf K
[Ti] Título:Differences in Dietary Glycemic Load and Hormones in New York City Adults with No and Moderate/Severe Acne.
[So] Source:J Acad Nutr Diet;117(9):1375-1383, 2017 Sep.
[Is] ISSN:2212-2672
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Glycemic index (GI) and glycemic load (GL) may be implicated in acne pathogenesis. OBJECTIVE: This cross-sectional study examined differences between GI/GL and biological factors associated with acne among adults with and without moderate/severe acne. Secondary objectives included examining differences between food-aggravated acne beliefs and acne-specific quality of life among adults with and without moderate/severe acne. DESIGN: As part of a cross-sectional study, participants completed a 5-day food record; blood draw to measure biological factors associated with acne (ie, glucose, insulin, insulin-like growth factor-1, insulin-like growth factor binding protein-3, and sex hormone-binding globulin concentrations); body composition assessment; and questionnaire to evaluate food-aggravated acne beliefs and acne-specific quality of life. Food records were analyzed using Nutrition Data Services for Research. PARTICIPANTS: Sixty-four participants (no acne, n=32; moderate/severe acne, n=32) from New York City, NY, were included in this study. STATISTICAL ANALYSIS: Independent sample t tests and Mann-Whitney tests examined differences in anthropometric measurements, dietary intakes, biological factors associated with acne, insulin resistance, and acne-specific quality of life between acne groups. A χ test for independence assessed differences in food-aggravated acne beliefs between acne groups. RESULTS: Participants with moderate/severe acne consumed greater total carbohydrate (P=0.003), available carbohydrate (P<0.001), percent energy from carbohydrate (P<0.001), and GL (P<0.001) compared to participants without acne. Participants with moderate/severe acne had greater insulin (P=0.002) and insulin-like growth factor-1 (P=0.009) concentrations, greater insulin resistance (P=0.001), and lower sex hormone-binding globulin (P=0.015) concentrations compared to participants without acne. Although there were no differences between groups, 61% of participants reported food-influenced acne. Participants with moderate/severe acne reported a lower quality of life compared to participants without acne (P<0.001). CONCLUSIONS: The results from this cross-sectional study suggest a relationship between dietary carbohydrate, including GL, and acne. Future research is necessary to determine the effect of medical nutrition therapy on biological factors associated with acne and acne severity.
[Mh] Termos MeSH primário: Acne Vulgar/sangue
Dieta/efeitos adversos
Carboidratos da Dieta/efeitos adversos
Carga Glicêmica
[Mh] Termos MeSH secundário: Acne Vulgar/etiologia
Acne Vulgar/psicologia
Adulto
Antropometria
Glicemia/análise
Distribuição de Qui-Quadrado
Estudos Transversais
Registros de Dieta
Ingestão de Alimentos
Feminino
Seres Humanos
Insulina/sangue
Resistência à Insulina
Proteína 1 de Ligação a Fator de Crescimento Semelhante à Insulina/sangue
Proteína 3 de Ligação a Fator de Crescimento Semelhante à Insulina/sangue
Masculino
Cidade de Nova Iorque
Qualidade de Vida
Globulina de Ligação a Hormônio Sexual/análise
Estatísticas não Paramétricas
Inquéritos e Questionários
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Dietary Carbohydrates); 0 (Insulin); 0 (Insulin-Like Growth Factor Binding Protein 1); 0 (Insulin-Like Growth Factor Binding Protein 3); 0 (Sex Hormone-Binding Globulin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170614
[St] Status:MEDLINE


  9 / 5242 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28540984
[Au] Autor:Seo IH; Lee HB; Kim S; Lee YJ; Jung DH
[Ad] Endereço:Department of Family Medicine, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:Inverse Relationship between Hepatic Steatosis and Alanine Aminotransferase with Sex Hormone-Binding Globulin in Men.
[So] Source:Yonsei Med J;58(4):731-736, 2017 Jul.
[Is] ISSN:1976-2437
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Sex hormone-binding globulin (SHBG) is a serum glycoprotein produced predominantly in hepatocytes. As such, the synthesis of SHBG could be associated with liver function and metabolic syndrome. Alanine aminotransferase (ALT) levels could reflect hepatocellular injury and insulin resistance; however, the relationship between hepatic steatosis and ALT with SHBG has not been investigated in humans. The objective of this study was to investigate the associations between SHBG and hepatocyte damage among Korean male patients with hepatic steatosis enrolled in a health examination program. MATERIALS AND METHODS: We performed a retrospective cross-sectional study with 922 participants who underwent routine health examinations. A total of 922 men with or without hepatic steatosis were divided into three groups. We analyzed the risk of lower serum SHBG levels with or without elevated serum ALT levels using odds ratios with 95% confidence intervals (CIs). RESULTS: A significantly increased risk of lower serum SHBG level was observed in the group with hepatic steatosis and ALT elevation (95% CI 1.591-4.681). CONCLUSION: In men with hepatic steatosis, we found that elevated serum ALT levels were associated with lower serum SHBG levels. This finding suggests that subjects with both hepatic steatosis and increased ALT should be considered to have low levels of SHBG.
[Mh] Termos MeSH primário: Alanina Transaminase/metabolismo
Fígado Gorduroso/enzimologia
Globulina de Ligação a Hormônio Sexual/metabolismo
[Mh] Termos MeSH secundário: Estudos Transversais
Feminino
Seres Humanos
Masculino
Meia-Idade
Razão de Chances
Padrões de Referência
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sex Hormone-Binding Globulin); EC 2.6.1.2 (Alanine Transaminase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2017.58.4.731


  10 / 5242 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28539237
[Au] Autor:Aranda G; Fernández-Rebollo E; Pradas-Juni M; Hanzu FA; Kalko SG; Halperin I; Mora M
[Ad] Endereço:Group of Endocrine Disorders, IDIBAPS, Barcelona, Spain; Department of Endocrinology and Nutrition, Hospital Clinic, Barcelona, Spain.
[Ti] Título:Effects of sex steroids on the pattern of methylation and expression of the promoter region of estrogen and androgen receptors in people with gender dysphoria under cross-sex hormone treatment.
[So] Source:J Steroid Biochem Mol Biol;172:20-28, 2017 Sep.
[Is] ISSN:1879-1220
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Cross-sex hormone therapy (CHT) is critical for phenotypical and physiological transition in adults with gender dysphoria (GD). However, the impact of the CHT onto the molecular level/epigenetic regulation has not been comprehensively addressed. We postulate that CHT in GD could drive changes at the androgen receptor (AR), estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2), affecting their DNA methylation pattern and mRNA expression that may influence in the phenotypical changes associated to CHT. We carried out a prospective observational study on individuals with a diagnosis of GD. 18 subjects (no previous CHT): 12 female to male (FtoM) and 6 male to female (MtoF). An Epityper Mass array TM method was used to study the DNA methylation and Real-time PCR quantitative reverse transcription PCR (qRT-PCR) was used to quantify the gene expression. The analysis of AR, ESR1 and ESR2 receptor was performed at baseline, 6 and 12 months after CHT. No differences in DNA methylation of ESR were found in MtoF, while DNA methylation was increased in FtoM at 6 and 12 months of CHT. The AR showed a significant increase of methylation in MtoF group after 12 months of estrogenic treatment. Regarding the expression analysis, AR expression was significantly decreased in FtoM upon CHT treatment. AR, ESR1 and ESR2 methylation were correlated with anthropometric, metabolic and hormonal parameters in FtoM and MtoF. Our results support that CHT is associated to epigenetic changes that might affect the response to treatment with sex steroids.
[Mh] Termos MeSH primário: Acetato de Ciproterona/uso terapêutico
Estradiol/análogos & derivados
Receptor alfa de Estrogênio/genética
Receptor beta de Estrogênio/genética
Disforia de Gênero/tratamento farmacológico
Receptores Androgênicos/genética
Testosterona/análogos & derivados
[Mh] Termos MeSH secundário: Adolescente
Adulto
Antropometria
Metilação de DNA/efeitos dos fármacos
Esquema de Medicação
Epigênese Genética
Estradiol/uso terapêutico
Receptor alfa de Estrogênio/metabolismo
Receptor beta de Estrogênio/metabolismo
Feminino
Hormônio Foliculoestimulante/genética
Hormônio Foliculoestimulante/metabolismo
Disforia de Gênero/genética
Disforia de Gênero/metabolismo
Disforia de Gênero/patologia
Seres Humanos
Hormônio Luteinizante/genética
Hormônio Luteinizante/metabolismo
Masculino
Prolactina/genética
Prolactina/metabolismo
Regiões Promotoras Genéticas
Estudos Prospectivos
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Receptores Androgênicos/metabolismo
Globulina de Ligação a Hormônio Sexual
Transdução de Sinais
Testosterona/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (AR protein, human); 0 (ESR2 protein, human); 0 (Estrogen Receptor alpha); 0 (Estrogen Receptor beta); 0 (RNA, Messenger); 0 (Receptors, Androgen); 0 (Sex Hormone-Binding Globulin); 0 (estrogen receptor alpha, human); 3XMK78S47O (Testosterone); 4KM2BN5JHF (Cyproterone Acetate); 4TI98Z838E (Estradiol); 9002-62-4 (Prolactin); 9002-67-9 (Luteinizing Hormone); 9002-68-0 (Follicle Stimulating Hormone); H16A5VCT9C (testosterone undecanoate); OKG364O896 (estradiol valerate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE



página 1 de 525 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde